Aim: to study the activity of pro-inflammatory cytokine interleukin 6 (IL-6) and determine its significance as a marker of emerging cardiometabolic risks in adolescent male patients with obesity, taking into account clinical and biochemical manifestations of metabolic syndrome (MS). Patients and Methods: 96 adolescent male patients aged 16–18 years with obesity of class 1–3 were examined. IL-6 levels, serum lipidogram,basal and glucose-stimulated concentrations of insulin during a standard oral glucose tolerance test were determined in all patients. Results and Discussion: in patients with obesity, the IL-6 content was higher than in healthy adolescents (p=0.03) in the absence of a significant association with BMI. Besides, the IL-6 content increased in individuals with high insulin resistance (HOMA-IR index >5.0) versus the patients whose index value was lower (p=0.04). The IL-6 count in adolescents with blood triglycerides >1.7 mmol/l was higher than in patients with normal concentrations (p=0.023). Adding that, a significant increase in IL-6 content was shown in adolescents with hypertension (p=0.04). MS with three or more signs in accordance with the International Diabetes Federation (IDF) criteria was diagnosed in more than half of the surveyed adolescents with obesity. IL-6 levels were significantly elevated in patients with MS signs, especially in those with its complete form. An increase in IL-6 production in adolescents with obesity correlated with the stages of dyslipidemia, induced hyperinsulinemia and hypertension, which allows to use this indicator as a marker of emerging MS. KEYWORDS: interleukin 6, obesity, adolescents, metabolic syndrome, dyslipidemia, insulin resistance. FOR CITATION: Puzikova O.Z., Churyukina E.V., Moskovkina A.V., Popova V.A., Afonin A.A., Kravchenko L.V. Clinical and diagnostic significance of interleukin 6 as a marker of metabolic inflammation in adolescents with obesity. Russian Medical Inquiry. 2024;8(7):421–426 (in Russ.). DOI: 10.32364/2587-6821-2024-8-7-8.